Lantern Pharma Inc. Other Comprehensive Income (Loss), Net of Tax
Lantern Pharma Inc. (LTRN) reported Other Comprehensive Income (Loss), Net of Tax of -$4.12 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossNetOfTax · last filed 2026-08-14
- Lantern Pharma Inc. other comprehensive income (loss), net of tax for the quarter ending 2026-06-30 was -$4.12K.
- Lantern Pharma Inc. other comprehensive income (loss), net of tax for the quarter ending 2026-03-31 was -$61.07K.
- Lantern Pharma Inc. other comprehensive income (loss), net of tax for the quarter ending 2025-12-31 was -$14.90K, a 108.31% decline year-over-year.
- Lantern Pharma Inc. other comprehensive income (loss), net of tax for the quarter ending 2025-09-30 was -$7.71K.
- Lantern Pharma Inc. other comprehensive income (loss), net of tax for fiscal 2025 was -$128.56K, a 149.17% decline from fiscal 2024.
- Lantern Pharma Inc. other comprehensive income (loss), net of tax for fiscal 2024 was $261.45K, a 0.94% decline from fiscal 2023.
- Lantern Pharma Inc. other comprehensive income (loss), net of tax for fiscal 2023 was $263.93K.
- Lantern Pharma Inc. other comprehensive income (loss), net of tax for fiscal 2022 was -$278.70K.
| Period end | Other Comprehensive Income (Loss), Net of Tax 3 month | Other Comprehensive Income (Loss), Net of Tax 6 month | Other Comprehensive Income (Loss), Net of Tax 9 month | Other Comprehensive Income (Loss), Net of Tax 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$4.12K 10-Q · filed 2026-08-14 | -$65.19K 10-Q · filed 2026-08-14 | -$80.09K derived: sum of 3 quarters · filed 2026-08-14 | -$87.80K derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | -$61.07K 10-Q · filed 2026-08-14 | -$75.97K derived: sum of 2 quarters · filed 2026-08-14 | -$83.68K derived: sum of 3 quarters · filed 2026-08-14 | -$167.37K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | -$14.90K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | -$22.61K derived: sum of 2 quarters · filed 2026-03-30 | -$106.30K derived: sum of 3 quarters · filed 2026-08-14 | -$128.56K 10-K · filed 2026-03-30 |
| 2025-09-30 | -$7.71K 10-Q · filed 2025-11-12 | -$91.40K derived: sum of 2 quarters · filed 2026-08-14 | -$113.66K 10-Q · filed 2025-11-12 | $65.60K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | -$83.69K 10-Q · filed 2026-08-14 | -$105.95K 10-Q · filed 2026-08-14 | $73.31K derived: sum of 3 quarters · filed 2026-08-14 | $54.63K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | -$22.26K 10-Q · filed 2026-08-14 | $157.00K derived: sum of 2 quarters · filed 2026-08-14 | $138.32K derived: sum of 3 quarters · filed 2026-08-14 | $129.87K derived: sum of 4 quarters · filed 2026-08-14 |
| 2024-12-31 | $179.25K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $160.57K derived: sum of 2 quarters · filed 2026-03-30 | $152.13K derived: sum of 3 quarters · filed 2026-03-30 | $261.45K 10-K · filed 2026-03-30 |
| 2024-09-30 | -$18.68K 10-Q · filed 2025-11-12 | -$27.12K derived: sum of 2 quarters · filed 2025-11-12 | $82.20K 10-Q · filed 2025-11-12 | $113.53K derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | -$8.45K 10-Q · filed 2025-11-12 | $100.88K 10-Q · filed 2025-08-13 | $132.21K derived: sum of 3 quarters · filed 2025-11-12 | $255.25K derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-03-31 | $109.32K 10-Q · filed 2025-11-12 | $140.65K derived: sum of 2 quarters · filed 2025-11-12 | $263.70K derived: sum of 3 quarters · filed 2025-11-12 | $301.54K derived: sum of 4 quarters · filed 2025-11-12 |
| 2023-12-31 | $31.33K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $154.38K derived: sum of 2 quarters · filed 2025-03-27 | $192.22K derived: sum of 3 quarters · filed 2025-03-27 | $263.93K 10-K · filed 2025-03-27 |
| 2023-09-30 | $123.05K 10-Q · filed 2024-11-07 | $160.88K derived: sum of 2 quarters · filed 2024-11-07 | $232.59K 10-Q · filed 2024-11-07 | $296.24K derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $37.84K 10-Q · filed 2024-11-07 | $109.55K 10-Q · filed 2024-08-08 | $173.20K derived: sum of 3 quarters · filed 2024-11-07 | $86.64K derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-03-31 | $71.71K 10-Q · filed 2024-11-07 | $135.36K derived: sum of 2 quarters · filed 2024-11-07 | $48.80K derived: sum of 3 quarters · filed 2024-11-07 | $11.79K derived: sum of 4 quarters · filed 2024-11-07 |
| 2022-12-31 | $63.65K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-18 | -$22.91K derived: sum of 2 quarters · filed 2024-03-18 | -$59.92K derived: sum of 3 quarters · filed 2024-03-18 | -$278.70K 10-K · filed 2024-03-18 |
| 2022-09-30 | -$86.55K 10-Q · filed 2023-11-08 | -$123.57K derived: sum of 2 quarters · filed 2023-11-08 | -$342.35K 10-Q · filed 2023-11-08 | -$332.35K derived: sum of 4 quarters · filed 2023-11-08 |
| 2022-06-30 | -$37.01K 10-Q · filed 2023-11-08 | -$255.79K 10-Q · filed 2023-08-09 | -$245.79K derived: sum of 3 quarters · filed 2023-11-08 | -$300.92K derived: sum of 4 quarters · filed 2023-11-08 |
| 2022-03-31 | -$218.78K 10-Q · filed 2023-11-08 | -$208.78K derived: sum of 2 quarters · filed 2023-11-08 | -$263.90K derived: sum of 3 quarters · filed 2023-11-08 | -$311.47K derived: sum of 4 quarters · filed 2023-11-08 |
| 2021-12-31 | $10.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-20 | -$45.12K derived: sum of 2 quarters · filed 2023-03-20 | -$92.69K derived: sum of 3 quarters · filed 2023-03-20 | -$92.69K 10-K · filed 2023-03-20 |
| 2021-09-30 | -$55.12K 10-Q · filed 2022-11-07 | -$102.69K derived: sum of 2 quarters · filed 2022-11-07 | -$102.69K 10-Q · filed 2022-11-07 | |
| 2021-06-30 | -$47.56K 10-Q · filed 2022-11-07 | -$47.56K 10-Q · filed 2022-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B | |
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B | |
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B | |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |